Skip to main content
SpringerLink
Log in

Pharmacological Interventions

  • Chapter
The Psychological Impact of Acute and Chronic Illness: A Practical Guide for Primary Care Physicians

  • 755 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Schwenk TL, Evans DL, Laden SK, Lewis L. Treatment outcome and physicians-patient communication in primary care patients with chronic, recurrent depression. Am J Psychiatry. 2004;161:1892–1901.

    Article  PubMed  Google Scholar 

  2. Ornstein S, Stuart G, Jenkins R. Depression diagnoses and antidepressant use in primary care practices. J Fam Pract. 2000;49:68–72.

    PubMed  CAS  Google Scholar 

  3. Depression guideline panel. Depression in Primary Care. Clinical Practice Guideline, No. 5. Vol 2. Rockville, MD: Agency for Health Care Policy and Research; April 1993.

    Google Scholar 

  4. Mojitabai R. Diagnosing depression and prescribing antidepressants by primary care physicians: the impact of practice style variations. Ment Health Serv Res. 2002;4:109–118.

    Article  Google Scholar 

  5. Weilburg JB, O'Leary KM, Meigs JB, Hennen J, Stafford RS. Evaluation of the adequacy of outpatient antidepressant treatment. Psychiatr Serv. 2003;54: 1233–1239.

    Article  PubMed  Google Scholar 

  6. Wilson I, Duszynski K, Mant A. A 5-year follow-up of general practice patients experiencing depression. Fam. Pract. 2003;20:685–689.

    Article  PubMed  Google Scholar 

  7. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient–physician communication. J Am Med Assoc. 2002;288:1403–1409.

    Article  Google Scholar 

  8. Nierenberg AA Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry. 1999;60(suppl 22):7–11.

    PubMed  Google Scholar 

  9. Frank E, Karp JF, Rush AJ. Efficacy of treatments for major depression. Psychopharmacol Bull. 1993;29:457–475.

    PubMed  CAS  Google Scholar 

  10. AHCPR. Clinical practice guideline number 5: depression in primary care: treatment of major depression. Vol 2. Rockville, MD: United States Department of Health and Human Services, Agency for Health care Policy and Research; 1993 [AHCPR publication 93–0551].

    Google Scholar 

  11. Thase ME, Sullivan LR. Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs. 1995;4:261–277.

    Article  CAS  Google Scholar 

  12. Sammons M. Introduction: the politics and pragmatics of prescriptive authority. In: Sammons M, Levant RF, Paige RU, eds. Prescriptive Authority for Psychologists: a History and Guide. Washington, DC: American Psychological Association; 2003:3–31.

    Chapter  Google Scholar 

  13. Pettit JW, Voelz ZR, Joiner TE. Combined treatments for depression. In: Sammons M, Schmidt NB, eds. Combined Treatments for Medical Disorders. Washington, DC: American Psychological Association; 2001:131–159.

    Chapter  Google Scholar 

  14. Nemeroff CB, Heim C, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA. 2003;25:14293–14296 [E pub].

    Google Scholar 

  15. APA. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text rev. Washington, DC: American Psychiatric Association; 2000.

    Google Scholar 

  16. Whooley MA. Simon GE. Managing depression in medical outpatients. NEngl J Med. 2000;343:1942–1950.

    Article  PubMed  CAS  Google Scholar 

  17. Kjernisted KD. Long-term goals in the management of acute and chronic anxiety disorders. Can J Psychiatry. 2004;49(suppl 1):51S–63S.

    PubMed  Google Scholar 

  18. Perlis RH, Fraguas R, Fava M, et al. Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the sequenced treatment alternatives to relieve depression study. J Clin Psychiatry. 2005;66: 159–166.

    Article  PubMed  Google Scholar 

  19. Mulrow CD, Williams Jr JW, Chiquette E, et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med. 2000;108:54–64.

    Article  PubMed  CAS  Google Scholar 

  20. Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas medication algorithm project. Arch Gen Psychiatry. 2004;61:669–680.

    Article  PubMed  Google Scholar 

  21. Lam R, Kennedy SH. Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses. Can J Psychiatry. 2004;49 (suppl 1):17S–26S.

    PubMed  Google Scholar 

  22. Stahl SM. Essential Psychopharmacology of Depression and Bipolar Disorder. Cambridge: Cambridge University; 2000.

    Google Scholar 

  23. Green B. Focus on paroxetine. Curr Med Res Opin. 2003;19:13–21.

    Article  PubMed  CAS  Google Scholar 

  24. Furukawa TA, Streiner DL, Young LT. Antidepressants and benzodiazepine for major depression. Cochrane Database Syst Rev. 2001 [Art. No.: CD001026. DOI:10.1002/14651858.CD001026].

    Google Scholar 

  25. Culpepper L. Use of algorithms to treat anxiety in primary care. J Clin Psychiatry. 2003;64(suppl 2):30–33.

    PubMed  Google Scholar 

  26. Kapczinski F, Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev. 2003 [Art. No.: CD003592, DOI:10.1002/14651858.CD003592].

    Google Scholar 

  27. Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ. A proposed algorithm for improved recognition and treatment of the depression/anxiety spectrum in primary care. Prim Care Companion J Clin Psychiatry. 2001;3:44–52.

    Article  PubMed  Google Scholar 

  28. Fricchione G. Generalized anxiety disorder. N Engl J Med. 2004;351:675–682.

    Article  PubMed  CAS  Google Scholar 

  29. Stein DJ. Algorithms for primary care: an evidence-based approach to the pharmacology of depression and anxiety disorders. Prim Psychiatry. 2004;11:55–78.

    Google Scholar 

  30. Gorman JM. Treating generalized anxiety disorder. J Clin Psychiatry. 2003;64(suppl 2):24–29.

    PubMed  Google Scholar 

  31. Roy-Byrne PP, Wagner AW, Schraufnagel BS. Understanding and treating panic disorder in the primary care setting. J Clin Psychiatry. 2005;66(suppl 4):16–22.

    PubMed  Google Scholar 

  32. Pollack MH. The pharmacotherapy of panic disorder. J Clin Psychiatry. 2005;66(suppl 4):23–27.

    PubMed  CAS  Google Scholar 

  33. Kangas M, Henry JL, Bryant RA. Posttraumatic stress disorder following cancer: a conceptual and empirical review. Clin Psychol Rev. 2002;22:499–524.

    Article  PubMed  Google Scholar 

  34. Bankier B, Januzzi JL, Littman AB. The high prevalence of multiple psychiatric disorders in stable outpatients with coronary heat disease. Psychosom Med. 2004;66:645–650.

    Article  PubMed  Google Scholar 

  35. Stein DJ, Zungu-Dirwayi N, van der Linden GJH, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2000 [Art. No.: CD002795, DOI:10.1002/14651858.CD002795].

    Google Scholar 

  36. Albucher RC, Liberzon I. Psychopharmacological treatment in PTSD: a critical review. J Psychiatr Res. 2002;36:355–367.

    Article  PubMed  Google Scholar 

  37. Bernard SA, Brera E. Drug interactions in palliative care. J Clin Oncol. 2000;18:1780–1799.

    PubMed  CAS  Google Scholar 

  38. Preskorn SH, Flockhart D. Guide to psychiatric drug interactions. Prim Psychiatry. 2004;11:39–60.

    Google Scholar 

  39. Preskorn SH, Aldereman J, Chung M, et al. Pharmacokinetics of desipramine co-administered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994;2: 90–98.

    Google Scholar 

  40. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol. 2003;17:517–38.

    Article  PubMed  CAS  Google Scholar 

  41. Chouinard G, Lefko-Singh K, Teboul E. Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. Cell Mol Neurobiol. 1999;19:533–552.

    Article  PubMed  CAS  Google Scholar 

  42. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part II. Psychosomatics. 2003;44:515–520.

    Article  PubMed  CAS  Google Scholar 

  43. Preskorn SH. Multiple medications, multiple considerations. J Psychiat Pract. 2001;48–52. http://www.pre3swkorn.com/columns/0101.html; Accessed 07.10.05.

  44. Muijsers RB, Plosker GL, Noble S. Sertraline: a review of its use in the management of major depressive disoder in elderely patients. Drugs Aging. 2002;19:377–392.

    Article  PubMed  CAS  Google Scholar 

  45. Brosen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001; 11:275–283.

    Article  PubMed  CAS  Google Scholar 

  46. Malin P, Wengel SP, Burke WJ. Escitalopram: better treatment for depression is through the looking glass. Expert Rev Neurother. 2004;4:769–779.

    Article  PubMed  CAS  Google Scholar 

  47. Crone CC, Gabriel GM. Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin Pharmacokinet. 2004;43:361–94.

    Article  PubMed  CAS  Google Scholar 

  48. Mulchahey JJ, Malik MS, Sabai M, Kasckow JW. Serotonin-selective reuptake inhibitors in the treatment of geriatric depression and related disorders. Int JNeuropsychopharmacol. 1999;2:121–127.

    Article  PubMed  CAS  Google Scholar 

  49. Flockhart D. Drug interactions and the cytochrome P450 system: the role of P450 2C19. Clin Pharmacokinet. 1995;29:45–52.

    Article  PubMed  CAS  Google Scholar 

  50. Ereshefsky L. Treating depression: potential drug–drug interactions. J Clin Psychopharmacol. 1996;16:50S–53S.

    Article  Google Scholar 

  51. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Int Med 2005;165:1095–1106.

    Article  CAS  Google Scholar 

  52. Johnson MD, Newkirk G, White JR. Clinically Significant Drug Interactions; 1999 [Post Grad Med 1999; 105]. http://www.postgradmed.com/issues/1999/0299/johnson.htm; Accessed.

  53. Hyttel J.Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol. 1994;9(suppl 1):19–26.

    Article  PubMed  Google Scholar 

  54. Fujishiro J, Taiichiro I, Onozawa K, Tsushima M. Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine. Eur J Pharmacol. 2002;454:183–188.

    Article  PubMed  CAS  Google Scholar 

  55. Masand PS, Gupta S. Long-term side effects of newer generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002;143:175–182.

    Google Scholar 

  56. Dennehy CE, Tsourounis C. Botanical (“herbal medications”) & nutritional supplements. In: Katzung BG, ed. Basic and Clinical Pharmacology. New York: Lange Medical Books/McGraw-Hill;2001:1088–1103.

    Google Scholar 

  57. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St. John's wort. J Psychopharmacol. 2004;18:262–276.

    Article  PubMed  CAS  Google Scholar 

  58. Young RC, Meyers BS. Psychophramacology. In: Sadovoy J, Lazarus LW, Jarvik LF, etal., eds. Comprehensive Review of Geriatric Psychiatry II. Washington, DC: American Psychiatric Press; 1996:755–817.

    Google Scholar 

  59. Julien RM. A Primer of Drug Action. New York: Worth Publishers; 2001.

    Google Scholar 

  60. Fiellin DA, Reid C, O'Connor PG. Screening for alcohol problems in primary care. Arch Int Med. 2000;160:1977–1989.

    Article  CAS  Google Scholar 

  61. Mayfield D, McLeod G, Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry. 1974;131:1121–1123.

    PubMed  CAS  Google Scholar 

  62. Zarcone VP. Sleep hygiene. In: Kryger MH, Roth T, Dement WC, eds. Principals and Practice of Sleep Medicine. 3rd ed. Philadelphia: W.B. Saunders Company; 2000:657–661.

    Google Scholar 

  63. Carrillo JA, Dahl ML, Svensson JO, etal. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther. 1996;60:183–190.

    Google Scholar 

  64. Carrillo JA, Benitez J.Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000;39: 127–153.

    Google Scholar 

  65. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352: 1112–1120.

    Article  PubMed  CAS  Google Scholar 

  66. Vitiello B, Swedo S. Antidepressant medications in children. N Engl J Med. 2004;350:1489–1491.

    Article  PubMed  CAS  Google Scholar 

  67. FDA public health advisory: suicidality in adults being treated with antidepressant medications. http://www.fda.gov/cder/drug/advisory/SSRI200507.htm; Accessed 23.12.05.

  68. Yerevanian BI, Koek RJ, Feusner JD, Hwang S, Mintz J.Antidepressants and suicidal behavior in unipolar depression. Acta Psychiatr Scand. 2004;110:452–458.

    Google Scholar 

  69. Fava GA. Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry. 2003;64:123–133.

    PubMed  CAS  Google Scholar 

  70. Barak Y, Olmer A, Aizenberg D. Antidepressants reduce the risk of suicide among elderly depressed patients. Neuropsychopharmacology. 2006;31: 178–181.

    PubMed  CAS  Google Scholar 

  71. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomized controlled clinical trials. BMJ. 2005;330:396.

    Article  PubMed  CAS  Google Scholar 

  72. Lenzer J.FDA warns that antidepressants may increase suicidality in adults. BMJ. 2005;331:70.

    Google Scholar 

  73. Zajecka J, Tracy KA, Mitchell S. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. J Clin Psychiatry. 1997;58:291–297.

    PubMed  CAS  Google Scholar 

  74. Berigan TR, Cannard AW, Cannard KR. Transient paroxysmal, shock-like paresthesias associated with paroxetine initiation. J Clin Psychiatry. 1997;58: 175–76.

    PubMed  CAS  Google Scholar 

  75. Hu XH, Bull SA, Hunkeler EM, etal. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: Patient report versus physician estimate. J Clin Psychiatry. 2004;65:959–965.

    Google Scholar 

  76. Landén M, Högberg B, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. J Clin Psychiatry 2005;66:100–106.

    Article  PubMed  Google Scholar 

  77. Schulberg HC, Katon W, Simon GE, Rush AJ. Treating major depression in primary care practice. Arch Gen Psychiatry. 1998;55:1121–1127.

    Article  PubMed  CAS  Google Scholar 

  78. Stahl SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. New York: Cambridge University Press; 2000.

    Google Scholar 

Download references

Editor information

Editors and Affiliations

  1. Langley Porter Psychiatric Institute, University of California, San Francisco, 94143, San Francisco, CA

    Tamara McClintock Greenberg Psy.D., M.S.

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

(2007). Pharmacological Interventions. In: Greenberg, T.M. (eds) The Psychological Impact of Acute and Chronic Illness: A Practical Guide for Primary Care Physicians. Springer, New York, NY. https://doi.org/10.1007/978-0-387-38298-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-38298-2_5

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-33682-4

  • Online ISBN: 978-0-387-38298-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation